Castle Biosciences (NASDAQ:CSTL) Posts Earnings Results, Misses Estimates By $0.12 EPS

Castle Biosciences (NASDAQ:CSTL - Get Free Report) released its earnings results on Monday. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.12), Zacks reports. The business had revenue of $87.99 million during the quarter, compared to analysts' expectations of $80.40 million. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. Castle Biosciences updated its FY 2025 guidance to EPS.

Castle Biosciences Trading Down 2.4 %

Shares of CSTL stock traded down $0.42 during trading hours on Friday, reaching $16.79. 380,690 shares of the stock traded hands, compared to its average volume of 402,443. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $484.76 million, a PE ratio of 83.95 and a beta of 1.19. The business has a fifty day moving average price of $19.83 and a 200 day moving average price of $25.61. Castle Biosciences has a 1-year low of $15.70 and a 1-year high of $35.84.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,130 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $19.52, for a total transaction of $41,577.60. Following the transaction, the insider now directly owns 78,335 shares in the company, valued at approximately $1,529,099.20. This represents a 2.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 27,454 shares of company stock valued at $553,030. 6.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on CSTL shares. Robert W. Baird lifted their price objective on Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Canaccord Genuity Group reduced their target price on Castle Biosciences from $42.00 to $37.00 and set a "buy" rating on the stock in a research note on Tuesday. Lake Street Capital reduced their price objective on shares of Castle Biosciences from $40.00 to $35.00 and set a "buy" rating for the company in a research note on Tuesday. Finally, Guggenheim set a $30.00 price target on Castle Biosciences and gave the company a "buy" rating in a research note on Friday, March 28th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $37.50.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.